Stelexis Therapeutics, LLC

In January 2019, Stelexis Therapeutics, LLC, a New York-based cancer therapeutics company, announced that it closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre‐cancerous stem cells.